Key terms
About ME
23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ME news
Apr 18
10:32am ET
M&A News: 23andMe (NASDAQ:ME) Soars on CEO’s Take-Private Intention
Apr 18
8:22am ET
23andMe Forms Special Committee for Strategic Governance
Apr 18
8:04am ET
23andMe announces CEO’s intention to pursue potential take-private
Apr 15
8:50pm ET
23andMe price target lowered to 47c from 85c at Citi
Apr 15
8:40pm ET
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and 23andMe Holding (ME)
Apr 11
9:14am ET
WW appoints new executive leaders
Mar 29
1:02pm ET
23andMe CAO Kathy Hibbs Retires, Guy Chayoun Steps In
Mar 20
7:37am ET
23andMe initiates Phase 1 trial for 23ME-01473
Mar 19
8:14am ET
23andMe launches feature connecting customers to historic individuals
Mar 06
7:36am ET
23andMe launches new genetic report on forms of cancer
Feb 08
6:20am ET
23andMe price target lowered to 85c from 90c at Citi
Feb 08
6:20am ET
Analysts Conflicted on These Healthcare Names: Denali Therapeutics (DNLI), BridgeBio Pharma (BBIO) and 23andMe Holding (ME)
Feb 07
8:55pm ET
Buy Rating for 23andMe on Strategic Restructuring and Potential for Shareholder Value Enhancement
Feb 07
4:13pm ET
23andMe reduces FY24 revenue view to $215M-$220M, consensus $245.45M
Feb 07
4:05pm ET
23andMe reports Q3 EPS (58c), consensus (14c)
Feb 07
2:20pm ET
23andMe weighs splitting consumer, therapeutics units, Bloomberg says
Feb 01
1:06am ET
Maintaining a Hold: Balancing 23andMe’s Innovative Therapeutic Prospects with Early-Stage Development Risks
Jan 31
7:31am ET
23andMe announces FDA clearance of IND application for 23ME-01473
No recent press releases are available for ME
ME Financials
Key terms
Ad Feedback
ME Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ME Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
